title: The Interplay of Dengue Virus Morphological Diversity and Human Antibodies.
abstract: Dengue virus (DENV) infects ∼400 million people annually, and there is no available vaccine or therapeutics. It is not clear why candidate vaccines provide only modest protection. In addition to the presence of four different dengue serotypes, there is also structural heterogeneity in DENV infectious particles, even within a strain. This severely complicates the development of vaccines and therapeutics. The currently known different morphologies of DENV are: immature, partially mature, compact mature, and expanded mature forms of the virus. In this review I describe these forms of the virus, their infectivity, and how antibodies could recognize these morphologies. I also discuss possible vaccine and antibody therapeutic formulations to protect against all morphologies.
authors.affiliation: Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore 169857, Singapore; Centre for BioImaging Sciences, National University of Singapore, Singapore 117557, Singapore. Electronic address: sheemei.lok@duke-nus.edu.sg.
authors.forename: Shee-Mei
authors.initials: SM
authors.lastname: Lok
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D000940:Antigenic Variation; D003715:Dengue / Q000276:immunology* / Q000628:therapy / Q000821:virology*; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D003716:Dengue Virus / Q000145:classification* / Q000276:immunology*; D006801:Humans; D008958:Models, Molecular; D011485:Protein Binding
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053059:Dengue Vaccines
keywords: antibodies; dengue virus; morphologies; therapeutics; vaccines